On ECHEMI
Home > Drugs > Jincheng Haisi Pharmaceutical Co., Ltd.
Jincheng Haisi Pharmaceutical Co., Ltd.
  • Founded in:

    1997-12-30
  • Country:

    China China
  • Address:

    Wangtai, Jincheng City, Shanxi Province
  • Tax NO.:

    91140500111208832X
  • Registered Funds:

    148.512131 yuan
  • Email:

Related Drugs
Water-soluble vitamins for injection
The main ingredients of this product are multivitamins, and the components in each 1000 bottles are:
Name Description Content CAS NO. Registered Holders
Various vitamins

This product is a part of intravenous nutrition, used to supplement the daily physiological needs of various water-soluble vitamins so that the body's relevant biochemical reactions can proceed normally.

More

This product is a part of intravenous nutrition, used to supplement the daily physiological needs of various water-soluble vitamins so that the body's relevant biochemical reactions can proceed normally.

0
Meclofenoxate hydrochloride
Name Description Content CAS NO. Registered Holders
Meclofenoxate hydrochloride

Extract from the above information

More

Extract from the above information

3685-84-5 23
Diammonium Glycyrrhizinate for Injection
The main ingredient of this product is diammonium glycyrrhizinate. Its chemical name is: 20β-carboxyl-11-oxo-n-oleanol-12-ene-3β-yl-2-O-β-D-glucopyranosiduronic acid-a-D-glucopyranosiduronic acid diammonium salt.
Name Description Content CAS NO. Registered Holders
Diammonium glycyrrhizinate

It has strong anti-inflammatory, liver cell membrane protection and liver function improvement effects. It can reduce the increase of serum alanine aminotransferase and aspartate aminotransferase caused by carbon tetrachloride, thioacetamide and D-galactosamine, reduce the morphological damage of D-galactosamine to the liver and improve the chronic damage of immune factors to the liver morphology.

More

It has strong anti-inflammatory, liver cell membrane protection and liver function improvement effects. It can reduce the increase of serum alanine aminotransferase and aspartate aminotransferase caused by carbon tetrachloride, thioacetamide and D-galactosamine, reduce the morphological damage of D-galactosamine to the liver and improve the chronic damage of immune factors to the liver morphology.

79165-06-3 35
Omeprazole Sodium for Injection
Omeprazole sodium.
Name Description Content CAS NO. Registered Holders
Omeprazole sodium

This product is a proton pump inhibitor of gastric parietal cells. It can specifically inhibit the secretory microtubules and tubular vesicles in the cytoplasm of the parietal cell apical membrane, thereby effectively inhibiting the secretion of gastric acid. Since H, K-ATPase is the last process of acid secretion of parietal cells, this product has a strong acid inhibition ability. It can not only non-competitively inhibit gastric acid secretion caused by gastrin, histamine, choline, food, and stimulation of the vagus nerve, but also inhibit part of the basic gastric acid secretion that is not affected by choline or H2 receptor blockers. It also has a strong and lasting inhibitory effect on gastric acid secretion caused by dibutyl cyclic adenosine monophosphate (DCAMP) stimulation that cannot be inhibited by H2 receptor antagonists. In addition, this product also has an inhibitory effect on pepsin secretion, has no obvious change in gastric mucosal blood flow, and does not affect body temperature, gastric cavity temperature, arterial blood pressure, venous hemoglobin, arterial oxygen partial pressure, carbon dioxide partial pressure and arterial blood pH.

More

This product is a proton pump inhibitor of gastric parietal cells. It can specifically inhibit the secretory microtubules and tubular vesicles in the cytoplasm of the parietal cell apical membrane, thereby effectively inhibiting the secretion of gastric acid. Since H, K-ATPase is the last process of acid secretion of parietal cells, this product has a strong acid inhibition ability. It can not only non-competitively inhibit gastric acid secretion caused by gastrin, histamine, choline, food, and stimulation of the vagus nerve, but also inhibit part of the basic gastric acid secretion that is not affected by choline or H2 receptor blockers. It also has a strong and lasting inhibitory effect on gastric acid secretion caused by dibutyl cyclic adenosine monophosphate (DCAMP) stimulation that cannot be inhibited by H2 receptor antagonists. In addition, this product also has an inhibitory effect on pepsin secretion, has no obvious change in gastric mucosal blood flow, and does not affect body temperature, gastric cavity temperature, arterial blood pressure, venous hemoglobin, arterial oxygen partial pressure, carbon dioxide partial pressure and arterial blood pH.

95510-70-6 25
Omeprazole Sodium for Injection
Omeprazole sodium.
Name Description Content CAS NO. Registered Holders
Omeprazole sodium

This product is a proton pump inhibitor of gastric parietal cells. It can specifically inhibit the secretory microtubules and tubular vesicles in the cytoplasm of the parietal cell apical membrane, thereby effectively inhibiting the secretion of gastric acid. Since H, K-ATPase is the last process of acid secretion of parietal cells, this product has a strong acid inhibition ability. It can not only non-competitively inhibit gastric acid secretion caused by gastrin, histamine, choline, food, and stimulation of the vagus nerve, but also inhibit part of the basic gastric acid secretion that is not affected by choline or H2 receptor blockers. It also has a strong and lasting inhibitory effect on gastric acid secretion caused by dibutyl cyclic adenosine monophosphate (DCAMP) stimulation that cannot be inhibited by H2 receptor antagonists. This product also has an inhibitory effect on pepsin secretion, has no obvious change in gastric mucosal blood flow, and does not affect body temperature, gastric cavity temperature, arterial blood pressure, venous hemoglobin, arterial oxygen partial pressure, carbon dioxide partial pressure and arterial blood pH.

More

This product is a proton pump inhibitor of gastric parietal cells. It can specifically inhibit the secretory microtubules and tubular vesicles in the cytoplasm of the parietal cell apical membrane, thereby effectively inhibiting the secretion of gastric acid. Since H, K-ATPase is the last process of acid secretion of parietal cells, this product has a strong acid inhibition ability. It can not only non-competitively inhibit gastric acid secretion caused by gastrin, histamine, choline, food, and stimulation of the vagus nerve, but also inhibit part of the basic gastric acid secretion that is not affected by choline or H2 receptor blockers. It also has a strong and lasting inhibitory effect on gastric acid secretion caused by dibutyl cyclic adenosine monophosphate (DCAMP) stimulation that cannot be inhibited by H2 receptor antagonists. This product also has an inhibitory effect on pepsin secretion, has no obvious change in gastric mucosal blood flow, and does not affect body temperature, gastric cavity temperature, arterial blood pressure, venous hemoglobin, arterial oxygen partial pressure, carbon dioxide partial pressure and arterial blood pH.

95510-70-6 25
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.